{"entity":{"id":"nct07551778","kind":"trial","name":"Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of cetuximab and bevacizumab (glioblastoma use) in colorectal cancer, run by BOE Technology Group Co., Ltd., not yet recruiting.","summary":"Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors is a phase 1/2, interventional study registered as NCT07551778 by BOE Technology Group Co., Ltd., with a registry enrolment figure of 42 participants, started 2026-08 and due to reach its primary completion in 2028-04. Interventions recorded: NK Cells; NK cells + PD-(L)1 inhibitor + pemetrexed as first-line maintenance therapy; NK cells + cetuximab/bevacizumab + capecitabine as first-line maintenance therapy; NK cells + PD-(L)1 inhibitor + VEGF inhibitor as first-line maintenance therapy; NK cells + PD-(L)1 inhibitor + capecitabine or S-1 as first-line maintenance therapy. Conditions listed: NSCLC (Advanced Non-small Cell Lung Cancer); Colorectal Cancer; Advanced Solid Tumors; Advanced Hepatocellular Carcinoma (HCC); GC/GEJC. Primary outcome: Dose-Limiting Toxicity (DLT); Adverse Events (AE). Colorectal eligibility wording from the registry: \"* Histologically/cytologically confirmed locally advanced unresectable or metastatic (unresectable Stage III or Stage IV per AJCC 8th Edition) colorectal adenocarcinoma;\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07551778","url":"https://clinicaltrials.gov/study/NCT07551778"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["monoclonal-antibody"],"targets":[],"drugs":["cetuximab","bevacizumab-glioma"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07551778","phase":"1/2","setting":"An Exploratory Clinical Study to Evaluate the Safety and Efficacy of Allogeneic NK Cell Injection Combined With Standard Maintenance Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors","sponsor":"BOE Technology Group Co., Ltd.","enrolled":42,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07551778/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"},{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}